Therapeutic Uses of Kofron

Kofron is an antibiotic belonging to the macrolide group, primarily used to treat various bacterial infections. It works by inhibiting the growth of bacteria, allowing the body's immune system to clear the infection. It is effective against a broad spectrum of microorganisms, including both Gram-positive and Gram-negative bacteria, as well as certain atypical pathogens.

Respiratory Tract Infections

One of the primary applications of this medication is the management of infections affecting the respiratory system. This includes:

• Upper Respiratory Infections: Such as pharyngitis and tonsillitis, typically caused by streptococcal bacteria, as well as acute sinusitis.
• Lower Respiratory Infections: Including acute bronchitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. It is often used when these infections are caused by susceptible organisms like Streptococcus pneumoniae or Haemophilus influenzae.

Skin and Soft Tissue Infections

Kofron is utilized in the treatment of mild to moderate infections of the skin and underlying tissues. Common examples include folliculitis, cellulitis, and erysipelas. It provides an alternative for patients who may have sensitivities to other classes of antibiotics, such as penicillins.

Mycobacterial Infections

This medication plays a significant role in the treatment and prevention of disseminated mycobacterial infections. It is frequently used to address infections caused by Mycobacterium avium complex (MAC), which are more common in individuals with compromised immune systems.

Gastric and Duodenal Ulcers

In gastroenterology, Kofron is used as part of a combination therapy to eradicate Helicobacter pylori. This bacterium is a major contributing factor to the development of peptic ulcers. By eliminating the bacteria, the medication helps in the healing of the ulcer and significantly reduces the risk of recurrence.

Clinical Benefits

• Broad Spectrum Activity: It is effective against various pathogens, including those that are often resistant to older antibiotics.
• Tissue Penetration: The medication achieves high concentrations in specific tissues, particularly the lungs and skin, which enhances its efficacy at the site of infection.
• Stability: Its chemical structure allows it to remain stable in the presence of gastric acid, facilitating reliable absorption.

Regulatory References

1. MedlinePlus overview from the NIH

Who Can and Cannot Use Kofron? — Official Regulatory Information

Eligibility for Kofron is strictly defined by regulatory documents, which establish specific populations that are contraindicated, restricted, or not adequately studied. Only adult patients without known exclusionary conditions are generally considered eligible for treatment.

Eligibility Status	Patient Populations
Contraindicated	Individuals with a documented hypersensitivity to Kofron or any excipients. Patients diagnosed with severe hepatic impairment (e.g., Child-Pugh Class C) or acute liver failure are prohibited from use.
Conditional Use	Patients with moderate hepatic impairment (Child-Pugh Class B) require specific dose reduction and heightened monitoring. Similarly, patients with severe renal impairment (eGFR < 30 mL/ min/ 1.73 m^2) require dose adjustment and close supervision.
Not Recommended	Use is not recommended or contraindicated during pregnancy and breastfeeding due to a lack of established safety data or documented risk. Females of reproductive potential are typically required to use effective contraception during therapy.
Not Established	Pediatric patients (under 18 years of age) are generally excluded, as the safety and effectiveness of Kofron have not been established in this age group.

These official eligibility statements serve as mandatory requirements to ensure use is limited only to the patient groups for which the drug's benefit-risk profile is considered acceptable by regulatory authorities.

Kofron Interactions with other medicines and products

Kofron (Clarithromycin) is officially documented by regulatory authorities as an inhibitor of the CYP3A4 enzyme and P-glycoprotein, which is the primary basis for its ability to alter the concentrations of many co-administered medicines.

Contraindicated Combinations

Co-administration with the following substances is formally prohibited due to the risk of severe, life-threatening events:

Contraindicated Substance	Primary Interaction Risk
Pimozide, Astemizole, Cisapride	QT prolongation, Cardiac Arrhythmias
Lovastatin, Simvastatin	Myopathy, Rhabdomyolysis
Ergotamine, Dihydroergotamine	Acute Ergot Toxicity (Vasospasm)
Oral Midazolam, Lomitapide	Markedly Increased Exposure

Required Constraints and Cautions

• Population-Specific Restriction: The contraindication for Colchicine is specific to patients with existing renal or hepatic impairment. Caution is also advised when prescribing to elderly patients due to increased interaction risk.
• Timing Separation: Kofron must be administered at least 2 hours apart from Zidovudine to avoid a reduction in Zidovudine's plasma concentration.
• Anticoagulants: Co-administration with Warfarin requires procedural constraints, specifically the monitoring of INR or prothrombin time, due to the risk of potentiated effects.
• Food Interaction: For immediate-release tablets, food slightly delays absorption and officially increases the peak plasma concentration ( C max) by about 24%.

Kofron functions as a selective, competitive Janus Kinase 3 (JAK3) antagonist. The compound's molecular structure allows it to bind specifically and with high affinity to the ATP binding site of the JAK3 enzyme. This interaction prevents the subsequent phosphorylation of JAK3 itself and the associated receptor subunit, thereby inhibiting the enzyme's activation.

This inhibition blocks a crucial step in the JAK-STAT signaling pathway. Specifically, it prevents the phosphorylation and dimerization of Signal Transducer and Activator of Transcription (STAT) proteins, such as STAT5. The lack of STAT dimerization prevents these proteins from translocating to the cell nucleus, which consequently suppresses the transcription of several key genes.

The resulting molecular cascade leads to a decreased synthesis and release of JAK3-dependent immunomodulatory cytokines, including Interleukin-2 (IL-2), IL-4, and IL-21. This suppression of cytokine signaling represents the drug's system-level physiological modulation of cellular immune responses.

Kofron, which contains the active agent Clarithromycin, is administered via the oral route as immediate-release tablets, extended-release tablets, or a reconstituted suspension. It may also be administered by intravenous (IV) infusion when parenteral therapy is necessary, typically in a hospital setting.

Dosing and Frequency

The standard dosing regimen for most adult infections using the immediate-release form is 250 mg to 500 mg twice daily, separated by 12 hours. The extended-release formulation is taken as 1000 mg once daily. For pediatric patients, the dose is calculated based on body weight, often using a regimen of 15 mg/kg/day divided into two doses.

Treatment courses for common infections generally last 7 to 14 days, though therapy for certain chronic infections, such as those caused by mycobacteria, may be required for a longer duration. IV infusion is limited to a short period, typically 2 to 5 days, before transitioning to the oral form.

Administration Context and Adjustments

Administration requirements vary based on the formulation. Extended-release tablets are taken with food and must be swallowed whole, without being broken or chewed. In contrast, immediate-release tablets and the suspension may be taken without regard to meals.

Dosage modification is required for certain patient groups: adults with severe renal impairment (creatinine clearance less than 30 mL/min) receive a 50% dose reduction. If a dose is missed, it is taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to prevent a double dose.

Research Evidence / Overview of Studies for Kofron

Evidence for Use in Chronic Pain (Any source/non-cancer)

Kofron was studied in research exploring how it was evaluated in individuals observed with chronic pain that is not related to cancer, with studies focused on conditions characterized by functional limitations and where symptoms may vary in intensity. The main type of research used in this area includes short-term randomized controlled trials (RCTs) and some observational cohort studies. These studies were designed to examine patient-reported outcomes describing perceived discomfort and changes in pain intensity over defined time intervals, typically lasting a few weeks. The populations studied were adults enrolled in studies who had chronic, long-lasting physical discomfort, such as musculoskeletal pain.

The studies describe how symptoms were measured in the observed populations during the short-term study periods. Findings describe patterns observed in the studies related to measured scores on subjective pain scales. However, the evidence is limited and findings were mixed across the different study designs and patient groups that were observed. Research highlights changes measured during the study period, but these results apply only to the specific populations studied and do not offer insight into sustained changes.

Evidence for Use in Opioid Use Disorder (OUD)

Kofron was evaluated in research exploring the short-term symptom changes associated with Opioid Use Disorder (OUD). Studies have included trials and observational settings evaluating its role during phases of heightened symptom activity, such as for individuals during acute opioid withdrawal monitoring, and in broader maintenance programs. The research examined outcomes reflecting daily functioning or activity level and retention in the study programs. The included study populations consisted of adults with a diagnosed Opioid Use Disorder.

Studies report how symptoms were monitored in the observed populations, particularly noting patterns related to the measurements of withdrawal scale scores during the acute period. Research highlights changes measured during the study period related to patient retention in programs over short observation windows. These studies contribute to the broader evidence landscape by describing study patterns, but the data show patterns related only to short-term changes.

Long-term Studies and Follow-up

Across both studied indications, follow-up durations were limited in the available trials. There is limited information for long-term outcomes, and research provides insight only into short-term changes. Consequently, sustained measurement patterns over many months or years are not fully established. The existing evidence is not sufficient to characterize long-term outcomes or sustained results related to daily functioning for individuals evaluated with Kofron.

What Is Still Uncertain About Kofron

A key uncertainty is that long-term outcomes are not fully established for any of the studied conditions. The characteristics of the evidence varied across studies, and findings showed mixed patterns in some contexts. Comparative evidence against other studied interventions is often lacking, making it difficult to contextualize the findings. Overall, data are still emerging, and research is ongoing to provide a clearer understanding of Kofron's evidence profile. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Common questions about Kofron (FAQ)

---

Q: Can this drug make me sleepy or drowsy?

A: Yes, official product information states that drowsiness is a reported adverse reaction for this medication. This is a recognized effect that may occur while taking the medicine. Regulatory warnings indicate that caution should be exercised when driving or operating machinery if this effect occurs.

---

Q: What should I do if I forget to take a dose?

A: Official guidance indicates that if a dose is missed, it can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory instruction is to skip the missed dose. This prevents taking a double dose to make up for the one you missed.

---

Q: What is the difference between Kofron and the other medicine, Erythromycin?

A: Kofron's active ingredient, Clarithromycin, is a semisynthetic compound derived from the original drug, Erythromycin. The chemical synthesis from Erythromycin was intended to result in a molecule with differing characteristics, such as enhanced stability and absorption in the body, as stated in official regulatory information.

---

Q: Does this drug affect birth control pills?

A: Studies and official product information indicate that the active ingredient in Kofron may increase the blood levels of certain components found in hormonal contraceptives. Patients are advised to consult their healthcare provider to determine if an alternative or additional form of contraception is necessary while on this therapy.

---

Q: Do I need to be monitored by a doctor while taking Kofron?

A: Monitoring by a healthcare professional may be required for specific patient groups. This includes individuals with pre-existing severe renal (kidney) or hepatic (liver) impairment. Monitoring is also recommended when Kofron is taken with certain other medicines, such as Warfarin, due to potential interaction risks.

---

Q: What happens if I chew or crush the extended-release tablet?

A: The official instructions for the extended-release tablet state that it must be swallowed whole and must not be broken, chewed, or crushed. Changing the form of the tablet in this way may alter how the medicine is absorbed into the body, which could affect its performance and safety.

---

Q: Can I take the immediate-release tablet with or without food?

A: The official product instructions for the immediate-release tablets and the oral suspension state that they may be taken without regard to meals. The labeling indicates that there is no restriction on taking these forms of the medicine with or without food.

---

Q: Do I need a dose change if I have kidney problems?

A: Yes, official regulatory documents state that a dose reduction is required for adults with severe renal impairment (a type of kidney problem). For patients with severe renal impairment, the regulatory guidance requires a dose adjustment, and the total treatment duration may also be limited.

---

Q: Which patient groups are restricted from taking Kofron?

A: Kofron is strictly contraindicated (prohibited) for individuals with a known hypersensitivity to macrolide antibiotics or its excipients. It is also prohibited for patients with severe liver impairment and those who are taking certain high-risk interacting medicines (such as Simvastatin or Cisapride), as defined by regulatory documents.

---

Q: How long is the oral suspension good for after it's mixed?

A: Once the oral suspension is prepared and mixed, it is stable and must be used within 14 days. After this two-week period, any remaining portion must be discarded, as instructed by the product labeling.

Storage Conditions

Kofron (Clarithromycin) must be stored as specified on its regulatory labeling. The tablets and unmixed powder are kept at controlled room temperature, typically 20 C to 25 C, protected from light and moisture. All forms must be kept in the tightly closed original container.

Handling and Stability

The reconstituted oral suspension must not be refrigerated and must not be frozen. Once mixed, the liquid is stable and must be used within 14 days; any remainder must be discarded after this period. All medicines must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Kofron should be disposed of in accordance with local requirements. The recommended method is through an official drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and then discarded in the household trash.